PTCT PE Ratio & Valuation,Is PTCT Overvalued

PTCT Relative Valuation

PTCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTCT is overvalued; if below, it's undervalued.

Historical Valuation

PTC Therapeutics Inc (PTCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.90 is considered Undervalued compared with the five-year average of -12.04. The fair price of PTC Therapeutics Inc (PTCT) is between 3373.47 to 3398.48 according to relative valuation methord. Compared to the current price of 75.64 USD , PTC Therapeutics Inc is Undervalued By 97.76%.

Relative Value

Fair Zone

3373.47-3398.48

Current Price：75.64

97.76%

Undervalued

-49.34

146.01

EV/EBITDA

PTC Therapeutics Inc. (PTCT) has a current EV/EBITDA of 146.01. The 5-year average EV/EBITDA is 20.79. The thresholds are as follows: Strongly Undervalued below -368.15, Undervalued between -368.15 and -173.68, Fairly Valued between 215.25 and -173.68, Overvalued between 215.25 and 409.72, and Strongly Overvalued above 409.72. The current Forward EV/EBITDA of 146.01 falls within the Historic Trend Line -Fairly Valued range.

-185.82

EV/EBIT

PTC Therapeutics Inc. (PTCT) has a current EV/EBIT of -185.82. The 5-year average EV/EBIT is -19.67. The thresholds are as follows: Strongly Undervalued below -106.23, Undervalued between -106.23 and -62.95, Fairly Valued between 23.61 and -62.95, Overvalued between 23.61 and 66.89, and Strongly Overvalued above 66.89. The current Forward EV/EBIT of -185.82 falls within the Strongly Undervalued range.

6.90

PTC Therapeutics Inc. (PTCT) has a current PS of 6.90. The 5-year average PS is 4.34. The thresholds are as follows: Strongly Undervalued below 1.51, Undervalued between 1.51 and 2.92, Fairly Valued between 5.76 and 2.92, Overvalued between 5.76 and 7.18, and Strongly Overvalued above 7.18. The current Forward PS of 6.90 falls within the Overvalued range.

-42.61

P/OCF

PTC Therapeutics Inc. (PTCT) has a current P/OCF of -42.61. The 5-year average P/OCF is -34.27. The thresholds are as follows: Strongly Undervalued below -263.08, Undervalued between -263.08 and -148.68, Fairly Valued between 80.13 and -148.68, Overvalued between 80.13 and 194.54, and Strongly Overvalued above 194.54. The current Forward P/OCF of -42.61 falls within the Historic Trend Line -Fairly Valued range.

23.39

P/FCF

PTC Therapeutics Inc. (PTCT) has a current P/FCF of 23.39. The 5-year average P/FCF is 33.61. The thresholds are as follows: Strongly Undervalued below -457.03, Undervalued between -457.03 and -211.71, Fairly Valued between 278.93 and -211.71, Overvalued between 278.93 and 524.25, and Strongly Overvalued above 524.25. The current Forward P/FCF of 23.39 falls within the Historic Trend Line -Fairly Valued range.

PTC Therapeutics Inc (PTCT) has a current Price-to-Book (P/B) ratio of -38.82. Compared to its 3-year average P/B ratio of -8.97 , the current P/B ratio is approximately 332.88% higher. Relative to its 5-year average P/B ratio of 89.83, the current P/B ratio is about -143.21% higher. PTC Therapeutics Inc (PTCT) has a Forward Free Cash Flow (FCF) yield of approximately 11.61%. Compared to its 3-year average FCF yield of -3.04%, the current FCF yield is approximately -481.92% lower. Relative to its 5-year average FCF yield of -5.31% , the current FCF yield is about -318.54% lower.

-38.82

P/B

Median3y

-8.97

Median5y

89.83

11.61

FCF Yield

Median3y

-3.04

Median5y

-5.31

Competitors Valuation Multiple

The average P/S ratio for PTCT's competitors is 1323.70, providing a benchmark for relative valuation. PTC Therapeutics Inc Corp (PTCT) exhibits a P/S ratio of 6.90, which is -99.48% above the industry average. Given its robust revenue growth of 7.23%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PTCT increased by 67.57% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 3.09 to 8.46.

The secondary factor is the Revenue Growth, contributed 7.23%to the performance.

Overall, the performance of PTCT in the past 1 year is driven by P/E Change. Which is more unsustainable.

7.23%

196.79M → 211.01M

Revenue Growth

-113.89%

-54.20 → 7.53

Margin Expansion

174.23%

3.09 → 8.46

P/E Change

67.57%

45.14 → 75.64

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is PTC Therapeutics Inc (PTCT) currently overvalued or undervalued?

What is PTC Therapeutics Inc (PTCT) fair value?

PTCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of PTC Therapeutics Inc (PTCT) is between 3373.47 to 3398.48 according to relative valuation methord.

How does PTCT's valuation metrics compare to the industry average?

What is the current P/B ratio for PTC Therapeutics Inc (PTCT) as of Dec 15 2025?

As of Dec 15 2025, PTC Therapeutics Inc (PTCT) has a P/B ratio of -38.82. This indicates that the market values PTCT at -38.82 times its book value.

What is the current FCF Yield for PTC Therapeutics Inc (PTCT) as of Dec 15 2025?

As of Dec 15 2025, PTC Therapeutics Inc (PTCT) has a FCF Yield of 11.61%. This means that for every dollar of PTC Therapeutics Inc’s market capitalization, the company generates 11.61 cents in free cash flow.

What is the current Forward P/E ratio for PTC Therapeutics Inc (PTCT) as of Dec 15 2025?

As of Dec 15 2025, PTC Therapeutics Inc (PTCT) has a Forward P/E ratio of -49.34. This means the market is willing to pay $-49.34 for every dollar of PTC Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for PTC Therapeutics Inc (PTCT) as of Dec 15 2025?

As of Dec 15 2025, PTC Therapeutics Inc (PTCT) has a Forward P/S ratio of 6.90. This means the market is valuing PTCT at $6.90 for every dollar of expected revenue over the next 12 months.

PTCT Valuation